Eintrag weiter verarbeiten
Human immunodeficiency virus protease: A target for aids therapy
Gespeichert in:
| Zeitschriftentitel: | Drug Development Research |
|---|---|
| Personen und Körperschaften: | , |
| In: | Drug Development Research, 21, 1990, 1, S. 1-17 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Debouck, Christine Metcalf, Brian W. Debouck, Christine Metcalf, Brian W. |
|---|---|
| author |
Debouck, Christine Metcalf, Brian W. |
| spellingShingle |
Debouck, Christine Metcalf, Brian W. Drug Development Research Human immunodeficiency virus protease: A target for aids therapy Drug Discovery |
| author_sort |
debouck, christine |
| spelling |
Debouck, Christine Metcalf, Brian W. 0272-4391 1098-2299 Wiley Drug Discovery http://dx.doi.org/10.1002/ddr.430210102 <jats:title>Abstract</jats:title><jats:p>Human immunodeficiency virus, also called HIV, is the etiologic agent of acquired immune deficiency syndrome (AIDS). This retrovirus produces a small, dimeric aspartyl protease which specifically cleaves the precursor forms of the structural proteins and enzymes of the virus. This proteolytic activity is absolutely required for the production of mature, infectious viral particles and is therefore an attractive target for therapeutic intervention. Peptide analogues containing transition‐state mimics were synthesized and shown to inhibit the activity of the purified HIV protease in vitro to various extents. Most interestingly, the most potent inhibitors were shown to effectively block the protease in HIV‐infected cells and to impair the viral life cycle. Other approaches to interfere with the viral protease activity or production are also discussed.</jats:p> Human immunodeficiency virus protease: A target for aids therapy Drug Development Research |
| doi_str_mv |
10.1002/ddr.430210102 |
| facet_avail |
Online |
| finc_class_facet |
Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9kZHIuNDMwMjEwMTAy |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9kZHIuNDMwMjEwMTAy |
| institution |
DE-Bn3 DE-Brt1 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 |
| imprint |
Wiley, 1990 |
| imprint_str_mv |
Wiley, 1990 |
| issn |
1098-2299 0272-4391 |
| issn_str_mv |
1098-2299 0272-4391 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
debouck1990humanimmunodeficiencyvirusproteaseatargetforaidstherapy |
| publishDateSort |
1990 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Drug Development Research |
| source_id |
49 |
| title |
Human immunodeficiency virus protease: A target for aids therapy |
| title_unstemmed |
Human immunodeficiency virus protease: A target for aids therapy |
| title_full |
Human immunodeficiency virus protease: A target for aids therapy |
| title_fullStr |
Human immunodeficiency virus protease: A target for aids therapy |
| title_full_unstemmed |
Human immunodeficiency virus protease: A target for aids therapy |
| title_short |
Human immunodeficiency virus protease: A target for aids therapy |
| title_sort |
human immunodeficiency virus protease: a target for aids therapy |
| topic |
Drug Discovery |
| url |
http://dx.doi.org/10.1002/ddr.430210102 |
| publishDate |
1990 |
| physical |
1-17 |
| description |
<jats:title>Abstract</jats:title><jats:p>Human immunodeficiency virus, also called HIV, is the etiologic agent of acquired immune deficiency syndrome (AIDS). This retrovirus produces a small, dimeric aspartyl protease which specifically cleaves the precursor forms of the structural proteins and enzymes of the virus. This proteolytic activity is absolutely required for the production of mature, infectious viral particles and is therefore an attractive target for therapeutic intervention. Peptide analogues containing transition‐state mimics were synthesized and shown to inhibit the activity of the purified HIV protease in vitro to various extents. Most interestingly, the most potent inhibitors were shown to effectively block the protease in HIV‐infected cells and to impair the viral life cycle. Other approaches to interfere with the viral protease activity or production are also discussed.</jats:p> |
| container_issue |
1 |
| container_start_page |
1 |
| container_title |
Drug Development Research |
| container_volume |
21 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792342710228615177 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:39:51.866Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Human+immunodeficiency+virus+protease%3A+A+target+for+aids+therapy&rft.date=1990-01-01&genre=article&issn=1098-2299&volume=21&issue=1&spage=1&epage=17&pages=1-17&jtitle=Drug+Development+Research&atitle=Human+immunodeficiency+virus+protease%3A+A+target+for+aids+therapy&aulast=Metcalf&aufirst=Brian+W.&rft_id=info%3Adoi%2F10.1002%2Fddr.430210102&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792342710228615177 |
| author | Debouck, Christine, Metcalf, Brian W. |
| author_facet | Debouck, Christine, Metcalf, Brian W., Debouck, Christine, Metcalf, Brian W. |
| author_sort | debouck, christine |
| container_issue | 1 |
| container_start_page | 1 |
| container_title | Drug Development Research |
| container_volume | 21 |
| description | <jats:title>Abstract</jats:title><jats:p>Human immunodeficiency virus, also called HIV, is the etiologic agent of acquired immune deficiency syndrome (AIDS). This retrovirus produces a small, dimeric aspartyl protease which specifically cleaves the precursor forms of the structural proteins and enzymes of the virus. This proteolytic activity is absolutely required for the production of mature, infectious viral particles and is therefore an attractive target for therapeutic intervention. Peptide analogues containing transition‐state mimics were synthesized and shown to inhibit the activity of the purified HIV protease in vitro to various extents. Most interestingly, the most potent inhibitors were shown to effectively block the protease in HIV‐infected cells and to impair the viral life cycle. Other approaches to interfere with the viral protease activity or production are also discussed.</jats:p> |
| doi_str_mv | 10.1002/ddr.430210102 |
| facet_avail | Online |
| finc_class_facet | Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9kZHIuNDMwMjEwMTAy |
| imprint | Wiley, 1990 |
| imprint_str_mv | Wiley, 1990 |
| institution | DE-Bn3, DE-Brt1, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275 |
| issn | 1098-2299, 0272-4391 |
| issn_str_mv | 1098-2299, 0272-4391 |
| language | English |
| last_indexed | 2024-03-01T16:39:51.866Z |
| match_str | debouck1990humanimmunodeficiencyvirusproteaseatargetforaidstherapy |
| mega_collection | Wiley (CrossRef) |
| physical | 1-17 |
| publishDate | 1990 |
| publishDateSort | 1990 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Drug Development Research |
| source_id | 49 |
| spelling | Debouck, Christine Metcalf, Brian W. 0272-4391 1098-2299 Wiley Drug Discovery http://dx.doi.org/10.1002/ddr.430210102 <jats:title>Abstract</jats:title><jats:p>Human immunodeficiency virus, also called HIV, is the etiologic agent of acquired immune deficiency syndrome (AIDS). This retrovirus produces a small, dimeric aspartyl protease which specifically cleaves the precursor forms of the structural proteins and enzymes of the virus. This proteolytic activity is absolutely required for the production of mature, infectious viral particles and is therefore an attractive target for therapeutic intervention. Peptide analogues containing transition‐state mimics were synthesized and shown to inhibit the activity of the purified HIV protease in vitro to various extents. Most interestingly, the most potent inhibitors were shown to effectively block the protease in HIV‐infected cells and to impair the viral life cycle. Other approaches to interfere with the viral protease activity or production are also discussed.</jats:p> Human immunodeficiency virus protease: A target for aids therapy Drug Development Research |
| spellingShingle | Debouck, Christine, Metcalf, Brian W., Drug Development Research, Human immunodeficiency virus protease: A target for aids therapy, Drug Discovery |
| title | Human immunodeficiency virus protease: A target for aids therapy |
| title_full | Human immunodeficiency virus protease: A target for aids therapy |
| title_fullStr | Human immunodeficiency virus protease: A target for aids therapy |
| title_full_unstemmed | Human immunodeficiency virus protease: A target for aids therapy |
| title_short | Human immunodeficiency virus protease: A target for aids therapy |
| title_sort | human immunodeficiency virus protease: a target for aids therapy |
| title_unstemmed | Human immunodeficiency virus protease: A target for aids therapy |
| topic | Drug Discovery |
| url | http://dx.doi.org/10.1002/ddr.430210102 |